Startups channel feed – Endpoints News

Startups channel feed

With the clinic in sight, Greg Verdine's startup bags $178M for new class of targeted therapies

3 years ago

Plexxikon vets kick off new drug discovery outfit — with old assets and new target

3 years ago

European protein software startup Cradle launches with backing from Lyft, Twist CEOs

3 years ago

Following ASCO showing, Bert Vogelstein’s latest startup launches into recurrent cancer detection

3 years ago

The crew that sold its lead IL-2 program to Roche is back with $93M to work on more next-gen I/O drugs

3 years ago

Oral alternative to eye injections? Novo backs startup’s big plan to repurpose shelved drug

3 years ago

Updated: Two years after launch, Third Rock-backed neuro startup Faze Medicines is closing its doors — report

3 years ago

GSK vets theorize that a mitochondrial target may unlock Parkinson's and ALS treatments in new startup

3 years ago

Scoop: A SoftBank-backed biotech raises more funds after bagging $100M+ for fungi mining

3 years ago

Two former Stanford researchers nab a $41M launch round to learn the secrets of the ‘secretome’

3 years ago

Mining from plants and fungi, CNS startup takes leap into psychoactive drugs — complete with $30M to kick things off

3 years ago

'Rulebook of microbial ecology': Pianists launch Concerto to treat eczema, protect crops and get rid of BO

3 years ago

Exclusive: Mt. Everest almost got in the way of a tRNA biotech, but hC Bioscience climbs to Series A extension

3 years ago

Scoop: Calling off an IPO, a cancer and Covid-19 vaccine maker raises a Series C

3 years ago

A Chicago biotech skips the IPO in favor of late-stage Series D for a PhIII Tourette drug

3 years ago

Drug R&D hurdles hamper another biotech as a Jeff Aronin upstart shuts down

3 years ago

An NK cell therapy biotech pulls IPO ambitions weeks after second trial clearance

3 years ago

Leading a $60M launch round, RA Capital backs another 'toad venom' startup

3 years ago

Updated: Samsara backs ex-Gilead duo's amalgamation of NASH, liver drug assets from former employer, other biopharmas

3 years ago

That secretive ARCH biotech with two antibodies from MorphoSys? It’s now got $120M

3 years ago

Under hub-and-spoke biotech, serial founders launch new startup hoping to make gene therapies for the eye

3 years ago

Intrinsic wanted an IPO. Instead, it's a SPAC for the gut-brain microbiome biotech

3 years ago

Glyn Edwards takes chairman role at UK oncolytic virus startup emerging out of stealth

3 years ago

PD-L1 pioneer Lieping Chen, Rachel Humphrey spin out new biotech to break down the door on cold tumors

3 years ago

First page Previous page 35 36 373839 40 41 Next page Last page